Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 9 studies | 39% ± 22% | |
astrocyte | 9 studies | 28% ± 12% | |
GABAergic neuron | 8 studies | 37% ± 18% | |
endothelial cell | 7 studies | 27% ± 11% | |
oligodendrocyte precursor cell | 6 studies | 25% ± 11% | |
interneuron | 5 studies | 42% ± 25% | |
neuron | 4 studies | 22% ± 6% | |
fibroblast | 4 studies | 26% ± 6% | |
macrophage | 4 studies | 19% ± 3% | |
GABAergic interneuron | 3 studies | 23% ± 1% | |
microglial cell | 3 studies | 24% ± 4% | |
mesothelial cell | 3 studies | 22% ± 2% | |
hepatocyte | 3 studies | 36% ± 18% | |
type I pneumocyte | 3 studies | 19% ± 5% | |
type II pneumocyte | 3 studies | 21% ± 2% | |
transit amplifying cell | 3 studies | 21% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 12 studies | 28% ± 16% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 4972.29 | 180 / 180 | 100% | 14.38 | 429 / 430 |
prostate | 100% | 1183.33 | 245 / 245 | 100% | 7.24 | 500 / 502 |
intestine | 100% | 790.05 | 966 / 966 | 99% | 10.81 | 523 / 527 |
adrenal gland | 100% | 2939.93 | 258 / 258 | 99% | 15.33 | 227 / 230 |
stomach | 100% | 906.02 | 359 / 359 | 98% | 11.38 | 279 / 286 |
thymus | 100% | 510.44 | 651 / 653 | 98% | 6.04 | 592 / 605 |
esophagus | 100% | 851.18 | 1442 / 1445 | 97% | 11.33 | 177 / 183 |
pancreas | 98% | 386.76 | 323 / 328 | 96% | 7.69 | 170 / 178 |
uterus | 100% | 1417.85 | 170 / 170 | 93% | 8.33 | 429 / 459 |
lung | 99% | 592.98 | 575 / 578 | 93% | 7.49 | 1076 / 1155 |
liver | 100% | 486.01 | 225 / 226 | 92% | 5.79 | 375 / 406 |
skin | 100% | 681.57 | 1805 / 1809 | 92% | 7.54 | 433 / 472 |
breast | 100% | 514.95 | 459 / 459 | 90% | 6.84 | 1005 / 1118 |
kidney | 99% | 358.93 | 88 / 89 | 86% | 4.78 | 776 / 901 |
bladder | 100% | 950.05 | 21 / 21 | 79% | 5.84 | 398 / 504 |
brain | 97% | 686.43 | 2561 / 2642 | 62% | 3.87 | 439 / 705 |
spleen | 100% | 1115.34 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 554.32 | 1330 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 533.45 | 1197 / 1204 | 0% | 0 | 0 / 0 |
muscle | 99% | 761.02 | 796 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 8.68 | 43 / 45 |
lymph node | 0% | 0 | 0 / 0 | 93% | 6.54 | 27 / 29 |
eye | 0% | 0 | 0 / 0 | 91% | 4.08 | 73 / 80 |
heart | 85% | 256.66 | 736 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 71% | 348.65 | 660 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030017 | Cellular component | sarcomere |
GO_0016605 | Cellular component | PML body |
GO_0005737 | Cellular component | cytoplasm |
GO_0030414 | Molecular function | peptidase inhibitor activity |
GO_0005515 | Molecular function | protein binding |
GO_0032184 | Molecular function | SUMO polymer binding |
Gene name | SIMC1 |
Protein name | SUMO-interacting motif-containing protein 1 (Platform element for inhibition of autolytic degradation) |
Synonyms | PLEIAD C5orf25 |
Description | FUNCTION: Plays a role in SMC5-SMC6 complex recruitment for viral restriction. Forms a complex with SLF2 and this complex is required to recruit SMC5-SMC6 complex to PML nuclear bodies and sites of viral replication. .; FUNCTION: [Isoform 1]: Inhibits the protease activity of CAPN3. .; FUNCTION: [Isoform 5]: Inhibits the protease activity of CAPN3. . |
Accessions | ENST00000429602.7 [Q8NDZ2-5] ENST00000332772.4 [Q8NDZ2-4] ENST00000430704.6 [Q8NDZ2-3] ENST00000443967.5 [Q8NDZ2-1] ENST00000341199.10 [Q8NDZ2-3] Q8NDZ2 |